Lipocine Inc.
LPCN
$1.98
-$0.07-3.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.16% | -67.19% | -- | 595.09% | -98.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.16% | -67.19% | -- | 595.09% | -98.77% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 27.16% | -67.19% | -- | 595.09% | -98.77% |
| SG&A Expenses | 7.31% | 12.63% | -26.54% | -40.93% | -28.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.73% | 88.15% | 32.13% | -10.49% | -50.30% |
| Operating Income | -84.17% | -262.78% | -27.77% | 26.98% | -164.86% |
| Income Before Tax | -96.92% | -232.99% | -43.63% | 28.11% | -153.07% |
| Income Tax Expenses | -- | -- | -- | -- | 0.00% |
| Earnings from Continuing Operations | -96.90% | -232.99% | -43.63% | 28.12% | -153.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.90% | -232.99% | -43.63% | 28.12% | -153.08% |
| EBIT | -84.17% | -262.78% | -27.77% | 26.98% | -164.86% |
| EBITDA | -84.84% | -260.19% | -27.65% | 27.28% | -164.21% |
| EPS Basic | -54.98% | -225.21% | -41.89% | 28.23% | -152.75% |
| Normalized Basic EPS | -54.98% | -225.16% | -41.92% | 28.21% | -152.75% |
| EPS Diluted | -54.40% | -233.61% | -33.88% | 28.23% | -152.95% |
| Normalized Diluted EPS | -54.98% | -233.01% | -41.92% | 28.21% | -153.16% |
| Average Basic Shares Outstanding | 27.04% | 6.23% | 1.22% | 0.15% | 0.62% |
| Average Diluted Shares Outstanding | 27.04% | -0.03% | 1.22% | 0.15% | -0.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |